Xenon Reports Q1 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals reported Q1 2026 financial results highlighted by a cash position of $1.3 billion, which extends the company’s runway into 2029 following significant capital raises during the quarter. The company confirmed it anticipates submitting a New Drug Application for its lead asset azetukalner in Q3 2026, following positive Phase 3 X-TOLE2 data for focal onset seizures announced in March.
Key figures
- Revenue
- 0
- Runway
- into 2029
- Net loss
- 102300000
- Rd expenses
- 88500000
- Atm proceeds
- 130000000
- Public offering proceeds
- 707600000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.